A multicenter phase 1/2 PRadR study is currently investigating the safety and efficacy of 177Lu-PSMA for patients with metastatic ccRCC who progressed on 2 or more prior lines of therapy (NCT06059014).87 A case report of a patient with metastatic RCC treated with 177Lu-PSMA radioligand therapy demonstrated rapid washout of the radionuclide from the tumor, suggesting that PSMA-targeted radioligand formulations may have to be modified to prolong tumor retention for the treatment of RCC.88 The gene discussed is FOLH1; the disease is neoplasm.